Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Eye & ENT Hospital of Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A-eyedrops on Ocular Alignment and Binocular Vision

Not Applicable

Recruiting

Conditions: Exophoria
Exotropia
Myopia

Interventions: Drug: 0.05% atropine eye drops
Drug: placebo eye drops (0.1% sodium hyaluronate ophthalmic solution)
Drug: 0.01% atropine eye drops

First Posted Date: 2022-05-18

Last Posted Date: 2025-02-25

Lead Sponsor: Eye & ENT Hospital of Fudan University

Target Recruit Count: 339

Registration Number: NCT05379855

Locations: 🇨🇳
Eye and ENT Hospital, Fudan University, Shanghai, China

Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC

Phase 2

Recruiting

Conditions: Recurrent Nasopharyngeal Carcinoma

First Posted Date: 2022-04-28

Last Posted Date: 2022-05-10

Lead Sponsor: Eye & ENT Hospital of Fudan University

Target Recruit Count: 77

Registration Number: NCT05350891

Locations: 🇨🇳
The First Affiliated Hospital of USTC(University of Science and Technology of China), Hefei, Anhui, China
🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳
Fujian Provincial Hospital, Fuzhou, Fujian, China

and more 5 locations

Efficacy of Hearing-aid Treatment for Patients With Tinnitus and Co-existing Hearing Loss

Not Applicable

Conditions: Tinnitus, Subjective
Hearing Loss, High-Frequency

First Posted Date: 2022-04-25

Last Posted Date: 2022-04-25

Lead Sponsor: Eye & ENT Hospital of Fudan University

Target Recruit Count: 62

Registration Number: NCT05343026

An Observational Study of Clinical Treatments for Patients With Oropharyngeal Carcinoma

Recruiting

Conditions: Oropharynx Carcinoma

First Posted Date: 2022-04-22

Last Posted Date: 2022-04-22

Lead Sponsor: Eye & ENT Hospital of Fudan University

Target Recruit Count: 200

Registration Number: NCT05341479

Locations: 🇨🇳
Department of Otorhinolaryngology, Eye & ENT Hospital, Shanghai, Shanghai, China

Comparison of the Sedation Effect of Esketamine and Sevoflurane for Pediatric Ophthalmological Procedure

Not Applicable

Completed

Conditions: Adverse Event

Interventions: Drug: Esketamine
Drug: Sevoflurane

First Posted Date: 2022-04-11

Last Posted Date: 2024-03-26

Lead Sponsor: Eye & ENT Hospital of Fudan University

Target Recruit Count: 116

Registration Number: NCT05321160

Locations: 🇨🇳
Anesthesiology Department of Affiliated Eye and ENT Hospital, Fudan University, Shanghai, Shanghai, China

Penpulimab in Combination With Cetuximab as First-line Treatment in R/M SCCHN

Phase 2

Recruiting

Conditions: Head and Neck Neoplasms
Recurrent Disease
Metastatic Cancer

Interventions: Drug: Penpulimab combined with cetuximab

First Posted Date: 2022-03-02

Last Posted Date: 2023-10-18

Lead Sponsor: Eye & ENT Hospital of Fudan University

Target Recruit Count: 48

Registration Number: NCT05260671

Locations: 🇨🇳
Department of radiotherapy,The First Bethune Hospital of Jilin University, Changchun, Jilin, China
🇨🇳
Department of Radiotherapy, Eye & ENT Hospital of Fudan University, Shanghai, China

Tirelizumab Plus Surgery vs Surgery Alone for Recurrent Nasopharyngeal Carcinoma

Phase 2

Not yet recruiting

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Tirelizumab
Procedure: salvage surgery

First Posted Date: 2021-10-25

Last Posted Date: 2021-10-25

Lead Sponsor: Eye & ENT Hospital of Fudan University

Target Recruit Count: 80

Registration Number: NCT05092217

Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery

Phase 2

Not yet recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Nimotuzumab

First Posted Date: 2021-08-27

Last Posted Date: 2021-08-27

Lead Sponsor: Eye & ENT Hospital of Fudan University

Target Recruit Count: 95

Registration Number: NCT05024019

Locations: 🇨🇳
The First Affiliated Hospital of Zhejiang University, Hangzhou, China
🇨🇳
Zhejiang Cancer Hospital, Hangzhou, China
🇨🇳
Jiangsu Province Hospital, Nanjing, China

and more 3 locations

Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma

Phase 2

Recruiting

Conditions: Recurrent Nasopharyngeal Carcinoma

Interventions: Drug: Camrelizumab
Drug: Chemotherapy
Procedure: endoscopic surgery

First Posted Date: 2021-08-18

Last Posted Date: 2024-03-06

Lead Sponsor: Eye & ENT Hospital of Fudan University

Target Recruit Count: 100

Registration Number: NCT05011227

Locations: 🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China
🇨🇳
Fujian Provincial Hospital, Fuzhou, Fujian, China
🇨🇳
Shenzhen Second People's Hospital, Shenzhen, Guangdong, China

and more 4 locations

Comparison of Sedation by Esketamine and Sevoflurane

Phase 4

Conditions: Sevoflurane

Interventions: Drug: Sevoflurane
Drug: Esketamine

First Posted Date: 2021-08-18

Last Posted Date: 2022-04-05

Lead Sponsor: Eye & ENT Hospital of Fudan University

Target Recruit Count: 60

Registration Number: NCT05011214

Locations: 🇨🇳
Anesthesiology Department of Affiliated Eye and ENT Hospital, Fudan University, Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy